Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Rivoceranib Plus Paclitaxel in Advanced Gastric or Gastroesophageal Junction Carcinoma
KCT0007392Phase 2Not yet recruiting
- Sponsor
- HLB Cell
- Start
- Jun 2022
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, single-arm trial of Rivoceranib in gastric adenocarcinoma and esophagogastric junction cancer, sponsored by HLB Cell. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinomaesophagogastric junction cancer
Beyond the preview
Go deeper on KCT0007392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007392.